MedTrace Logo

Evaluation of the Effect in Platelet Count of Atorvastatin and N-acetyl Cysteine

NCT05551624 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2022-09-22

No results posted yet for this study

Summary

The purpose of this study is to assess the ability of Atorvastatin and N-acetyl cysteine to elevate the blood (serum) platelet count in patients with Immune Thrombocytopenia as a mean of a new treatment.

Conditions

  • Primary Immune Thrombocytopenia

Interventions

DRUG

Atorvastatin 40 Mg Oral Tablet + N-acetylcysteine 400 mg Oral tablet

Oral tablets administered daily, atorvastatin once a day and N-acetylcysteine every 8 hours

Sponsors & Collaborators

  • Hospital Civil de Guadalajara

    lead OTHER

Principal Investigators

  • Enrique Cervantes-Perez, MD, MSc · Hospital Civil de Guadalajara

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-04
Primary Completion
2019-12-11
Completion
2020-01-23

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05551624 on ClinicalTrials.gov